Tempus AI (TEM) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Tempus AI (TEM) right now is Explosive Revenue Growth with a Clear Path to Profitability: Tempus grew full-year 2025 revenue roughly 83% year-over-year to approximately $1.27 billion, then guided for $1.59 billion in 2026, representing continued strong growth. Revenue (FY2025, reported) is ~$1.27 billion. If that keeps playing out, the setup is favourable; the risk to it is tempus remains unprofitable on a GAAP basis, with a full-year 2025 net loss of $245 million (which included $136 million in stock-based compensation), and the path to sustained GAAP profitability is long; Q1 2026 showed a net loss of $125.9 million, widening 85% year-over-year, and EPS missed analyst estimates by 34%. No one can predict where TEM trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Tempus AI (TEM) higher?
Explosive Revenue Growth with a Clear Path to Profitability
Tempus grew full-year 2025 revenue roughly 83% year-over-year to approximately $1.27 billion, then guided for $1.59 billion in 2026, representing continued strong growth. Adjusted EBITDA improved by approximately $97 million in 2025 to nearly breakeven (negative $7.4 million), and the company guided for positive Adjusted EBITDA of approximately $65 million in 2026, signaling an inflection toward operational profitability.
Data Licensing as a High-Margin Flywheel
The Data and Applications segment, which includes Insights data licensing, grew 31% in 2025 to $316 million and carries higher margins than diagnostics. Because the incremental cost of licensing existing data is low, each new pharma contract adds disproportionately to gross profit. Net Revenue Retention in the Insights product was 140% as of 2024, indicating that existing customers expand their spend substantially year over year.
Network Effects and Moat from Scale
With more than 200 petabytes of multimodal clinical data, over 100 patents protecting core algorithms, and deep EMR integrations that embed Tempus into clinical workflows, the platform becomes harder to displace as it grows. Replicating this scale of longitudinal, linked clinical and molecular data would require years and hundreds of millions of dollars, raising switching costs for both health systems and pharmaceutical partners.
Expanding Addressable Market Beyond Oncology
Through acquisitions of Paige AI (digital pathology), OneOme (pharmacogenomics), and Ambry Genetics (hereditary conditions), Tempus has extended its platform well beyond its oncology roots. The company cites a $70 billion opportunity in biomarker tests across just oncology and neuropsychology, while its pharma partners collectively spent over $262 billion globally on R&D in 2023, a pool from which data and trial services can draw recurring revenue.
What could weigh on TEM?
Tempus remains unprofitable on a GAAP basis, with a full-year 2025 net loss of $245 million (which included $136 million in stock-based compensation), and the path to sustained GAAP profitability is long; Q1 2026 showed a net loss of $125.9 million, widening 85% year-over-year, and EPS missed analyst estimates by 34%. Reimbursement risk is material: a significant portion of Tempus's diagnostics revenue depends on favorable coverage decisions from CMS and private payers, and adverse rulings on NGS tests or laboratory-developed tests (LDTs) could reduce revenue per test sharply. Regulatory scrutiny of LDTs by the FDA, ongoing data privacy obligations under HIPAA, and the risk that competitors such as Guardant Health, Illumina, Roche, or PathAI develop comparable datasets or lower-priced tests could compress both volume growth and pricing power over time.
How to think about a TEM forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the TEM guide and whether TEM is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the TEM outlook
The bottom line: what is driving Tempus AI (TEM) is Explosive Revenue Growth with a Clear Path to Profitability, with revenue (fy2025, reported) at ~$1.27 billion. If that keeps playing out the setup is favourable; the risk is tempus remains unprofitable on a GAAP basis, with a full-year 2025 net loss of $245 million (which included $136 million in stock-based compensation), and the path to sustained GAAP profitability is long; Q1 2026 showed a net loss of $125.9 million, widening 85% year-over-year, and EPS missed analyst estimates by 34%. No one can predict the price, so treat any TEM forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around TEM with Walnut
Use Tempus AI as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Tempus AI (TEM)?
+
No one can reliably predict where TEM will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Tempus AI higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive TEM higher?
+
The main growth drivers are Explosive Revenue Growth with a Clear Path to Profitability; Data Licensing as a High-Margin Flywheel; Network Effects and Moat from Scale. Whether they play out is the real question, not a guaranteed path.
What are the risks to TEM?
+
Tempus remains unprofitable on a GAAP basis, with a full-year 2025 net loss of $245 million (which included $136 million in stock-based compensation), and the path to sustained GAAP profitability is long; Q1 2026 showed a net loss of $125.9 million, widening 85% year-over-year, and EPS missed analyst estimates by 34%. Reimbursement risk is material: a significant portion of Tempus's diagnostics revenue depends on favorable coverage decisions from CMS and private payers, and adverse rulings on NGS tests or laboratory-developed tests (LDTs) could reduce revenue per test sharply. Regulatory scrutiny of LDTs by the FDA, ongoing data privacy obligations under HIPAA, and the risk that competitors such as Guardant Health, Illumina, Roche, or PathAI develop comparable datasets or lower-priced tests could compress both volume growth and pricing power over time.
Will TEM stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Tempus AI's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is TEM a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the TEM "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.